Letters Trans-Pacific Partnership

Will Pharmac become a victim of its own success?

BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d4908 (Published 02 August 2011) Cite this as: BMJ 2011;343:d4908
  1. Rachel H Foster, research fellow1,
  2. Nick Wilson, associate professor1
  1. 1Department of Public Health, University of Otago, Wellington, New Zealand,
  1. rachel.foster-russell{at}otago.ac.nz

Moynihan’s article summarises well the issues surrounding New Zealand’s drug funding authority Pharmac and the Trans-Pacific Partnership trade agreement currently being negotiated with the US.1 Why are US drug companies lobbying against Pharmac when the New Zealand drug market is insignificant in global terms? Pharmac’s success has probably made it a target.

Pharmac operates within a …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe